MAPT and Alzheimer disease: Despite a limited number of participants, about 1400 in the first study and about 500 in the second, the following conclusions were made: Plasma levels of p-tau217 can be used to discriminate between AD and other neurodegenerative diseases with higher accuracy than either p-tau isoforms or well-established MRI-based biomarkers [51].